Journal
MOLECULAR AND CELLULAR BIOCHEMISTRY
Volume 316, Issue 1-2, Pages 177-186Publisher
SPRINGER
DOI: 10.1007/s11010-008-9831-4
Keywords
CK2; retina; endothelial; astrocyte; diabetes; neovascularization; hematopoietic stem cell; TBB; TBCA; emodin; DRB
Categories
Funding
- NCRR NIH HHS [M01 RR000425, M01 RR00425] Funding Source: Medline
- NEI NIH HHS [R01 EY013431-07, R01 EY007739, EY13431, EY07739, R01 EY012601, EY12601, EY12605, R01 EY013431] Funding Source: Medline
Ask authors/readers for more resources
Ubiquitous protein kinase CK2 participates in a variety of key cellular functions. We have explored CK2 involvement in angiogenesis. As shown previously, CK2 inhibition reduced endothelial cell proliferation, survival and migration, tube formation, and secondary sprouting on Matrigel. Intraperitoneally administered CK2 inhibitors significantly reduced preretinal neovascularization in a mouse model of proliferative retinopathy. In this model, CK2 inhibitors had an additive effect with somatostatin analog, octreotide, resulting in marked dose reduction for the drug to achieve the same effect. CK2 inhibitors may thus emerge as potent future drugs aimed at inhibiting pathological angiogenesis. Immunostaining of the retina revealed predominant CK2 expression in astrocytes. In human diabetic retinas, mRNA levels of all CK2 subunits decreased, consistent with increased apoptosis. Importantly, a specific CK2 inhibitor prevented recruitment of bone marrow-derived hematopoietic stem cells to areas of retinal neovascularization. This may provide a novel mechanism of action of CK2 inhibitors on newly forming vessels.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available